Research
Hormonal
Pharmacological treatment of hypertension significantly reduces major cardiovascular events, including heart failure, stroke, and mortality, regardless of baseline blood pressure levels.
If diagnosed with hypertension, adhere to prescribed pharmacological treatment. Fixed-dose combinations are often recommended to improve adherence and minimize side effects. The reduction in cardiovascular risk is substantial and consistent across different baseline risks.
StrongSupportsVERY_HIGH confidence
Systematic reviews and meta-analyses of trials have shown that a 10 mmHg reduction in SBP or a 5 mmHg reduction in DBP is associated with substantial reductions in all major cardiovascular events (about 40% in heart failure, 35% in stroke, 15% in coronary heart disease, 20% in cardiovascular mortality and 10% in all-cause mortality).
Why this rating
Based on systematic reviews and meta-analyses of large-scale randomized clinical trials.
Source
Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension
Bin Zhou et al. · Nature Reviews Cardiology · 2021
DOI 10.1038/s41569-021-00559-8
narrative_reviewCited 1,474×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Hypertension prevalence and mortality burden are significantly higher in low- and middle-income countries compared to high-income countries, with deaths attributable to high blood pressure increasing in Asia and sub-Saharan Africa.Strong
- Population-level interventions, specifically lowering sodium in packaged foods and increasing fruit/vegetable availability, effectively reduce blood pressure across entire populations.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →